Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. The Lancet. 2011;377(9770):1019–31.
Article
Google Scholar
Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer’s disease:implications for prevention trials. Neuron. 2014;84(3):608–22.
Article
CAS
Google Scholar
Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207–16.
Article
CAS
Google Scholar
Foster EM, Dangla-Valls A, Lovestone S, Ribe EM, Buckley NJ. Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. Front Neurosci. 2019;13:164.
Article
Google Scholar
Rosenthal SL, Wang X, Demirci FY, Barmada MM, Ganguli M, Lopez OL, et al. Beta-Amyloid Toxicity Modifier Genes and the Risk of Alzheimer’s Disease. Am J Neurodegener Dis. 2012;1(2):191–8.
Google Scholar
Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1088–93.
Article
CAS
Google Scholar
Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1094–9.
Article
CAS
Google Scholar
Nilselid AM, Davidsson P, Nagga K, Andreasen N, Fredman P, Blennow K. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int. 2006;48(8):718–28.
Article
CAS
Google Scholar
Sihlbom C, Davidsson P, Sjogren M, Wahlund LO, Nilsson CL. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer’s disease patients and healthy individuals. Neurochem Res. 2008;33(7):1332–40.
Article
CAS
Google Scholar
Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, et al. A potential endophenotype for Alzheimer’s disease: cerebrospinal fluid clusterin. Neurobiol Aging. 2016;37(208):e1–9.
Google Scholar
Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer’s disease. Brain Res Mol Brain Res. 2003;118(1–2):140–6.
Article
CAS
Google Scholar
Lidström AM, Hessea C, Rosengrena L, Fredmana P, Davidssona P, Blennow K. Normal levels of clusterin in cerebrospinal fluid in Alzheimer’s disease, and no change after acute ischemic stroke. J Alzheimers Dis. 2001;3(5):435–42.
Article
Google Scholar
Shi X, Xie B, Xing Y, Tang Y. Plasma Clusterin as a Potential Biomarker for Alzheimer’s Disease-A Systematic Review and Meta-analysis. Curr Alzheimer Res. 2019;16(11):1018–27.
Article
CAS
Google Scholar
Yang C, Wang H, Li C, Niu H, Luo S, Guo X. Association between clusterin concentration and dementia: a systematic review and meta-analysis. Metab Brain Dis. 2019;34(1):129–40.
Article
Google Scholar
Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27(5):909–18.
Article
CAS
Google Scholar
Matsubara E, Frangione B, Ghiso J. Characterization of Apolipoprotein J-Alzheimer’s Aβ. Interaction. 1995;270(13):7563–7.
CAS
Google Scholar
Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, et al. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1–42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol. 1995;136(1):22–31.
Article
CAS
Google Scholar
DeMattos RB, Cirrito JR, Parsadanian M, May PC, O’Dell MA, Taylor JW, et al. ApoE and Clusterin Cooperatively Suppress Abeta Levels and Deposition: Evidence that ApoE Regulates Extracellular Abeta Metabolism In Vivo. Neuron. 2004;41(2):193–202.
Article
CAS
Google Scholar
Yuste-Checa P, Trinkaus VA, Riera-Tur I, Imamoglu R, Schaller TF, Wang H, et al. The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model. Nat Commun. 2021;12(1):4863.
Article
CAS
Google Scholar
Jack CRJ, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539–47.
Article
CAS
Google Scholar
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.
Article
Google Scholar
Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201–9.
Article
Google Scholar
Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, et al. Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010;6(3):230–8.
Article
CAS
Google Scholar
Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li QX, et al. Method comparison study of the Elecsys(R) beta-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS. Clin Biochem. 2019;72:7–14.
Article
CAS
Google Scholar
Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, et al. Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods. 2014;11(2):149–55.
Article
CAS
Google Scholar
Tang Y, Lutz MW, Xing Y. A systems-based model of Alzheimer’s disease. Alzheimers Dement. 2019;15(1):168–71.
Article
Google Scholar
Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimers Dement. 2017;13(3):205–16.
Article
Google Scholar
Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer’s disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470–81.
Article
Google Scholar
Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T, et al. The cerebrospinal-fluid soluble form of Alzheimer’s amyloid beta is complexed to SP-40,40(apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J. 1993;293(Pt 1):27–30.
Article
CAS
Google Scholar
Wang Y, Qin X, Paudel HK. Amyloid beta peptide promotes lysosomal degradation of clusterin via sortilin in hippocampal primary neurons. Neurobiol Dis. 2017;103:78–88.
Article
CAS
Google Scholar
May P, Lampert-Etchells M, Johnson S, Poirier J, Masters J, Finch C. Dynamics of gene expression for a hip- pocampal glycoprotein elevated in Alzheimer’s disease and in response to experimental lesions in rat. Neuron. 1990;5(6):831–9.
Article
CAS
Google Scholar
Lidström AM, Bogdanovic N, Hesse C, Volkman I, Davidsson P, Blennow K. Clusterin (Apolipoprotein J) Protein Levels Are Increased in Hippocampus and in Frontal Cortex in Alzheimer’s Disease. Exp Neurol. 1998;154(2):511–21.
Article
Google Scholar
Chen F, Swartzlander DB, Ghosh A, Fryer JD, Wang B, Zheng H. Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology. Mol Neurodegener. 2021;16(1):5.
Article
Google Scholar
Miners JS, Clarke P, Love S. Clusterin levels are increased in Alzheimer’s disease and influence the regional distribution of Abeta. Brain Pathol. 2017;27(3):305–13.
Article
CAS
Google Scholar
Wojtas AM, Carlomagno Y, Sens JP, Kang SS, Jensen TD, Kurti A, et al. Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation. Acta Neuropathol Commun. 2020;8(1):210.
Article
CAS
Google Scholar
Holtzman DM. CSF biomarkers for Alzheimer’s disease: current utility and potential future use. Neurobiol Aging. 2011;32(Suppl 1):S4–9.
Article
CAS
Google Scholar
Giannakopoulos P, Kövari E, French LE, Viard I, Hof PR, Bouras C. Possible neuroprotective role of clusterin in Alzheimer’s disease: a quantitative immunocytochemical study. Acta Neuropathol. 1998;95(4):387–94.
Article
CAS
Google Scholar
Cordero-Llana O, Scott SA, Maslen SL, Anderson JM, Boyle J, Chowhdury RR, et al. Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells. Cell Death Differ. 2011;18(5):907–13.
Article
CAS
Google Scholar
Imhof A, Charnay Y, Vallet PG, Aronow B, Kovari E, French LE, et al. Sustained astrocytic clusterin expression improves remodeling after brain ischemia. Neurobiol Dis. 2006;22(2):274–83.
Article
CAS
Google Scholar
Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer’s disease. Neuron. 2013;80(6):1347–58.
Article
CAS
Google Scholar